KR102233744B1 - Composition for improvementing, preventing or treating leaky gut syndrome comprising fractions or extract of pepper leave - Google Patents
Composition for improvementing, preventing or treating leaky gut syndrome comprising fractions or extract of pepper leave Download PDFInfo
- Publication number
- KR102233744B1 KR102233744B1 KR1020190049157A KR20190049157A KR102233744B1 KR 102233744 B1 KR102233744 B1 KR 102233744B1 KR 1020190049157 A KR1020190049157 A KR 1020190049157A KR 20190049157 A KR20190049157 A KR 20190049157A KR 102233744 B1 KR102233744 B1 KR 102233744B1
- Authority
- KR
- South Korea
- Prior art keywords
- red pepper
- extract
- composition
- preventing
- hot water
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 99
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 42
- 235000002566 Capsicum Nutrition 0.000 title description 11
- 239000006002 Pepper Substances 0.000 title description 10
- 235000016761 Piper aduncum Nutrition 0.000 title description 10
- 235000017804 Piper guineense Nutrition 0.000 title description 10
- 235000008184 Piper nigrum Nutrition 0.000 title description 10
- 244000203593 Piper nigrum Species 0.000 title 1
- 240000004160 Capsicum annuum Species 0.000 claims abstract description 108
- 235000007862 Capsicum baccatum Nutrition 0.000 claims abstract description 107
- 239000001728 capsicum frutescens Substances 0.000 claims abstract description 107
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims abstract description 106
- 239000004480 active ingredient Substances 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 64
- 230000000968 intestinal effect Effects 0.000 claims description 32
- 235000009200 high fat diet Nutrition 0.000 claims description 29
- 235000013305 food Nutrition 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 19
- 108090001005 Interleukin-6 Proteins 0.000 claims description 15
- 102000004889 Interleukin-6 Human genes 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 40
- 230000000694 effects Effects 0.000 description 29
- 235000000346 sugar Nutrition 0.000 description 19
- 229920000642 polymer Polymers 0.000 description 17
- 239000013641 positive control Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000003925 fat Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 238000010171 animal model Methods 0.000 description 13
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 241000722363 Piper Species 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 230000003870 intestinal permeability Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 8
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 8
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 8
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 208000004232 Enteritis Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 206010009900 Colitis ulcerative Diseases 0.000 description 6
- 208000011231 Crohn disease Diseases 0.000 description 6
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 5
- 239000002861 polymer material Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 208000009137 Behcet syndrome Diseases 0.000 description 4
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 4
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 4
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 4
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 230000005965 immune activity Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- -1 sulfasalazine) Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 3
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940097043 glucuronic acid Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000008944 intestinal immunity Effects 0.000 description 3
- 208000023569 ischemic bowel disease Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
- 229960004963 mesalazine Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000002567 Capsicum annuum Nutrition 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000004221 Multiple Trauma Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001511 capsicum annuum Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000013227 male C57BL/6J mice Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UFLHIIWVXFIJGU-ARJAWSKDSA-N (Z)-hex-3-en-1-ol Chemical compound CC\C=C/CCO UFLHIIWVXFIJGU-ARJAWSKDSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 240000001844 Capsicum baccatum Species 0.000 description 1
- 244000185501 Capsicum chinense Species 0.000 description 1
- 235000018306 Capsicum chinense Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 240000000533 Capsicum pubescens Species 0.000 description 1
- 235000015855 Capsicum pubescens Nutrition 0.000 description 1
- 102100035605 Cas scaffolding protein family member 4 Human genes 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000593508 Garcinia Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000947106 Homo sapiens Cas scaffolding protein family member 4 Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 염증성 장질환 또는 장누수증후군 개선, 예방 또는 치료용 조성물에 관한 것으로, 고춧잎 추출물을 유효성분으로 함유하는 염증성 장질환 또는 장누수증후군 개선, 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for improving, preventing or treating inflammatory bowel disease or leaky gut syndrome, and to a composition for improving, preventing or treating inflammatory bowel disease or leaky gut syndrome, containing red pepper leaf extract as an active ingredient.
Description
본 발명은 염증성 장질환 또는 장누수증후군 개선, 예방 또는 치료용 조성물에 관한 것으로, 고춧잎 추출물을 유효성분으로 함유함으로써 염증성 장질환 또는 장누수증후군 예방, 개선 또는 치료를 위한 기능성 식품 및 약제 등에 유용하게 이용될 수 있다.The present invention relates to a composition for improving, preventing or treating inflammatory bowel disease or leaky gut syndrome, and is useful in functional foods and drugs for preventing, improving or treating inflammatory bowel disease or leaky gut syndrome by containing red pepper leaf extract as an active ingredient. Can be used.
인체의 장관은 음식물의 소화, 흡수, 배설이라는 기본적인 기능 이외에 장관 점막이 관내 미생물이나 이들의 부산물, 항원, 독소 등의 혈류로의 유입을 차단하는 방어벽으로서의 면역학적 기능을 수행하고 있다. 즉, 장점막은 외부 물질을 차단하는 장벽인 동시에 이들을 통과, 흡수시키는 이중적인 기능을 갖는다.In addition to the basic functions of digestion, absorption, and excretion of food, the intestinal tract of the human body performs an immunological function as a barrier to the intestinal mucosa blocking the inflow of microorganisms, their by-products, antigens, and toxins into the bloodstream. That is, the merit film is a barrier that blocks foreign substances and has a dual function of passing and absorbing them.
이러한 장관 기능에 문제가 생기면 그 자체로 인체의 영양공급에 문제가 생길뿐더러, 반복되는 변비, 설사, 복통 등의 증상이 일상생활을 크게 방해하기 때문에 장 건강은 매우 중요하다.Intestinal health is very important because if there is a problem with these intestinal functions, not only does it cause problems in the supply of nutrients to the human body by itself, and symptoms such as repetitive constipation, diarrhea, and abdominal pain greatly interfere with daily life.
염증성 장질환은 장에 만성적으로 염증이 생기는 병으로 발병원인과 완치방법은 아직까지 알려져 있지 않다. 일반적으로 크론병과 궤양성 대장염을 가르키는데, 크론병과 궤양성 대장염은 설사나 복통, 메스꺼움, 발열, 식욕부진, 체중 감소, 피로감 등의 증상을 보일 수 있다. 크론병은 주로 소장과 대장에서 많이 발생하지만, 궤양성 대장염은 대장에서만 발명한다. 이외에 우리나라에 비교적 흔한 장형 베체트병도 이에 속한다.Inflammatory bowel disease is a disease in which the intestine is chronically inflamed, and the cause of the disease and the cure method are not yet known. In general, it refers to Crohn's disease and ulcerative colitis. Crohn's disease and ulcerative colitis may show symptoms such as diarrhea, abdominal pain, nausea, fever, loss of appetite, weight loss, and fatigue. Crohn's disease occurs mainly in the small and large intestine, but ulcerative colitis is invented only in the large intestine. In addition to this, long-sized Behcet's disease, which is relatively common in Korea, also belongs to this.
이러한 염증성 장질환을 치료하기 위하여 사용되는 약물로는 스테로이드성 면역억제제, 프로스타글란딘 (prostaglandins)의 생성을 차단하는 5-아미노살리실산 (5-aminosalicylic acid; 5-ASA) 계통 약물 (예, 설파살라진 등), 메살라진 등이 사용되고 있는데, 이들은 염증성 장질환의 치료효과가 미미할 뿐만 아니라 복부허실 (fullness), 두통, 발진, 간질환, 백혈구 감소증, 무과립구증, 남성 불임 등의 심각한 부작용을 유발하기 때문에, 상기 치료제의 사용이 제한되고 있다. Drugs used to treat such inflammatory bowel disease include steroidal immunosuppressants, 5-aminosalicylic acid (5-ASA) drugs that block the production of prostaglandins (e.g., sulfasalazine), Mesalazine and the like are being used, and they cause serious side effects such as fullness, headache, rash, liver disease, leukopenia, agranulocytosis and male infertility, as well as having insignificant therapeutic effect on inflammatory bowel disease. Its use is restricted.
따라서, 부작용을 유발하지 않는 염증성 장질환 치료제를 개발할 수 있다면, 보다 안전하면서도 효과적으로 염증성 장질환 환자들을 치료할 수 있을 것으로 예상되고 있으나, 아직까지는 부작용이 없는 치료제가 개발되지 못하고 있는 실정이다Therefore, if it is possible to develop a therapeutic agent for inflammatory bowel disease that does not cause side effects, it is expected that it will be possible to treat patients with inflammatory bowel disease more safely and effectively, but a therapeutic agent without side effects has not been developed yet.
이러한 배경하에서, 본 발명자들은 부작용을 유발하지 않는 천연물로부터 유래된 염증성 장질환 치료제를 개발하기 위하여 예의 노력한 결과, 고춧잎 추출물을 포함하는 조성물이 염증성 장질환뿐만 아니라 장누수증후군의 치료에 효과가 있고, 장관 면역기능을 증진시킴을 확인하여 본 발명을 완성하였다.Under this background, the present inventors have made diligent efforts to develop a therapeutic agent for inflammatory bowel disease derived from natural products that do not cause side effects, and as a result, a composition containing red pepper leaf extract is effective in treating not only inflammatory bowel disease but also intestinal leak syndrome, The present invention was completed by confirming that it enhances the intestinal immune function.
본 발명의 목적은 고춧잎 추출물을 유효성분으로 하는 염증성 장질환 또는 장누수증후군 개선 또는 예방용 식품 조성물을 제공하는데 있다.It is an object of the present invention to provide a food composition for improving or preventing inflammatory bowel disease or leaky intestinal syndrome using red pepper leaf extract as an active ingredient.
본 발명의 다른 목적은 고춧잎 추출물을 유효성분으로 하는 염증성 장질환 또는 장누수증후군 예방 또는 치료용 약학 조성물을 제공하는데 있다.Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease or leaky intestinal syndrome, comprising red pepper leaf extract as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 고춧잎 추출물을 유효성분으로 하는 염증성 장질환 또는 장누수증후군 개선 또는 예방용 식품 조성물을 제공한다.In order to achieve the above object, the present invention provides a food composition for improving or preventing inflammatory bowel disease or leaky intestinal syndrome using red pepper leaf extract as an active ingredient.
상기 고춧잎 추출물은 물, 탄소수 1 내지 4개의 알코올 또는 이들의 혼합용매로 추출된 것일 수 있다.The red pepper leaf extract may be extracted with water, alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 조성물은 면역 활성을 증가시키고, 염증 반응을 억제하며, 염증 세포의 활성화를 감소시키는 것일 수 있다.The composition may increase immune activity, suppress an inflammatory response, and reduce activation of inflammatory cells.
상기 조성물은 IgA 발현을 증진시키고, IL-6의 발현과 LTB4 발현을 억제 또는 감소시키는 것일 수 있다.The composition may be one that enhances IgA expression and inhibits or reduces the expression of IL-6 and LTB 4.
상기 염증성 장질환은 크론병, 궤양성 대장염, 장형 베체트병, 감염성 장염, 허혈성 장질환 및 방사선 장염으로 이루어진 군에서 선택되는 질환일 수 있다.The inflammatory bowel disease may be a disease selected from the group consisting of Crohn's disease, ulcerative colitis, enteric Behcet's disease, infectious enteritis, ischemic bowel disease, and radiation enteritis.
상기 장누수증후군은 고지방 식이에 의해 유도된 것일 수 있다.The leaky gut syndrome may be induced by a high fat diet.
상기 목적을 달성하기 위하여, 본 발명은 고춧잎 추출물을 유효성분으로 하는 염증성 장질환 또는 장누수증후군 예방 또는 치료용 약학 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease or leaky intestinal syndrome, comprising red pepper leaf extract as an active ingredient.
상기 고춧잎 추출물은 물, 탄소수 1 내지 4개의 알코올 또는 이들의 혼합용매로 추출된 것일 수 있다.The red pepper leaf extract may be extracted with water, alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 조성물은 면역 활성을 증가시키고, 염증 반응을 억제하며, 염증 세포의 활성화를 감소시키는 것일 수 있다.The composition may increase immune activity, suppress an inflammatory response, and reduce activation of inflammatory cells.
상기 조성물은 IgA 발현을 증진시키고, IL-6의 발현과 LTB4 발현을 억제 또는 감소시키는 것일 수 있다.The composition may be one that enhances IgA expression and inhibits or reduces the expression of IL-6 and LTB 4.
상기 염증성 장질환은 크론병, 궤양성 대장염, 장형 베체트병, 감염성 장염, 허혈성 장질환 및 방사선 장염으로 이루어진 군에서 선택되는 질환일 수 있다.The inflammatory bowel disease may be a disease selected from the group consisting of Crohn's disease, ulcerative colitis, enteric Behcet's disease, infectious enteritis, ischemic bowel disease, and radiation enteritis.
상기 장누수증후군은 고지방 식이에 의해 유도된 것일 수 있다.The leaky gut syndrome may be induced by a high fat diet.
본 발명의 조성물은 고춧잎 추출물을 포함하는 것으로써, 염증을 억제하고 면역을 활성화시켜 염증성 장질환을 개선, 예방 또는 치료할 수 있다. 또한 본 발명의 조성물은 장내 투과성을 강화하여 장누수증후군을 개선, 예방 또는 치료하는 효과를 갖는다.The composition of the present invention includes a red pepper leaf extract, thereby suppressing inflammation and activating immunity to improve, prevent or treat inflammatory bowel disease. In addition, the composition of the present invention has the effect of improving, preventing or treating intestinal leak syndrome by enhancing intestinal permeability.
도 1은 정상 사료군(NC), 양성 대조군(GC), 제1실험군(WEPL50) 및 제2실험군(WEPL100)에 대한 혈청 내 IgA의 농도를 측정하여 나타낸 그래프이다.
도 2는 정상 사료군(NC), 고지방 식이군(HF), 양성 대조군(GC), 제1실험군(WEPL50) 및 제2실험군(WEPL100)에 대한 혈청 내 사이토카인 IL-6 발현양을 측정하여 나타낸 그래프이다.
도 3은 정상 사료군(NC), 고지방 식이군(HF), 양성 대조군(GC), 제1실험군(WEPL50) 및 제2실험군(WEPL100)에 대한 혈청 내 사이토카인 leukotriene B4(LTB4) 발현양을 측정하여 나타낸 그래프이다.
도 4는 정상 사료군(NC), 고지방 식이군(HFD), 양성 대조군(GC), 제1실험군(WEPL50) 및 제2실험군(WEPL100)에서의 FITC-dextran 검출농도를 시간에 따라 측정하여 나타낸 그래프이다.
도 5는 도 4로부터 측정된 결과의 곡선아래 면적을 계산하여 그래프로 나타낸 것이다.1 is a graph showing the measurement of the concentration of IgA in serum for the normal feed group (NC), the positive control group (GC), the first experimental group (WEPL50), and the second experimental group (WEPL100).
2 is a measurement of the expression level of cytokine IL-6 in serum for the normal feed group (NC), the high fat diet group (HF), the positive control group (GC), the first experimental group (WEPL50), and the second experimental group (WEPL100). This is the graph shown.
Figure 3 is a normal feed group (NC), high fat diet group (HF), positive control group (GC), the first experimental group (WEPL50) and the second experimental group (WEPL100) in serum cytokine leukotriene B4 (LTB 4 ) expression amount It is a graph showing by measuring.
Figure 4 shows the detection concentration of FITC-dextran measured over time in a normal feed group (NC), a high fat diet group (HFD), a positive control group (GC), a first experimental group (WEPL50), and a second experimental group (WEPL100). It is a graph.
5 is a graph showing the area under the curve of the result measured from FIG. 4.
본 발명은 고춧잎 추출물을 유효성분으로 하는 염증성 장질환 또는 장누수증후군 개선, 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for improving, preventing or treating inflammatory bowel disease or leaky intestinal syndrome, using red pepper leaf extract as an active ingredient.
이하, 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명 고춧잎 추출물을 유효성분으로 하는 염증성 장질환 또는 장누수증후군 개선, 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for improving, preventing or treating inflammatory bowel disease or leaky intestinal syndrome, using red pepper leaf extract as an active ingredient.
고추(Capsicum annuum)는 열대성 식물로 가지과(Solanaceae)에 속하는 한해살이풀로 분류되며, 전 세계적으로 가장 많이 섭취하고 있는 채소 중 하나이다. 우리나라에서는 주로 늦봄부터 여름에 걸쳐 재배되며, 김치의 주재료로써 오래전부터 식재료로 사용됐다. 현재 전 세계적으로 알려진 고추의 품종은 20~30여종이 있으며, 그중 Capsicum annuum, Capsicum frutescens, Capsicum chinense, Capsicum baccatum, Capsicum pubescens 등이 가장 많이 재배되고 있다. 고추는 비타민과 무기질을 풍부하게 함유하고 있을 뿐만 아니라, carotenoid, quercetin, luteolin 및 capsaicinoids와 같은 페놀성 화합물을 다량 함유하고 있다고 보고되고 있으나, 고추 잎에 대한 연구는 미비한 실정이다.Pepper ( Capsicum annuum ) is a tropical plant, classified as an annual plant belonging to the Solanaceae family , and is one of the most consumed vegetables worldwide. In Korea, it is cultivated mainly from late spring to summer, and has been used as a food ingredient for a long time as the main ingredient of kimchi. Currently, there are about 20 to 30 varieties of peppers known worldwide, of which Capsicum annuum, Capsicum frutescens, Capsicum chinense, Capsicum baccatum, and Capsicum pubescens are the most cultivated. Red pepper is not only rich in vitamins and minerals, but it is reported that it contains a large amount of phenolic compounds such as carotenoid, quercetin, luteolin and capsaicinoids, but studies on red pepper leaves are insufficient.
본 발명에서 '장누수증후군' 또는 'leaky gut syndrome; LGS'이란, 장점막세포는 일정한 세포 사이의 간극을 유지하다가 소화 흡수 과정이 일어나는 동안 어떠한 자극이나 손상이 가해지면서 세포 사이의 틈으로 고분자 물질이 왕복할 수 있는 장점막 투과성이 증가되는 현상을 나타내는 것으로, 장벽의 기능을 제대로 하지 못하여 혈액 내 고분자 물질이 장관내 관강으로 누수되거나 관강 내의 고분자 물질이 직접 혈액으로 들어가는 현상(새는 장 상태; leaky gut)으로 인해 유발되는 증상을 총괄하여 의미한다. 상기 증상들은 노화, 알레르기, 다발성 외상, 류마티스 관절염, 염증성 대장질환, 만성피로 증후군, 과민성 증후군 등의 다양한 임상적 상태로 나타난다. 또한 장점막 투과성의 증가나 장점막의 손상으로 인해 병원체, 항원, 부패물질 등이 장점막 내로 유입되어 염증반응이 일어나고 내독소가 혈류로 유입되어 장내세균 전위(bacterial translocation), 장관내독소혈증(intestinal endotoxemia) 등을 야기하여 각종 염증반응 및 면역 반응이 나타나게 된다.In the present invention,'leaky gut syndrome' or'leaky gut syndrome'; LGS' refers to a phenomenon in which intestinal membrane cells maintain a certain gap between cells, and during the process of digestion and absorption, any stimulation or damage is applied, thereby increasing the permeability of the intestinal membrane in which a polymer material can reciprocate through the gap between cells. It collectively refers to symptoms caused by a phenomenon in which a polymer material in the blood leaks into the intestinal lumen due to a failure to function properly in the intestine or a phenomenon in which a polymer material in the lumen directly enters the blood (leaky gut). These symptoms appear in various clinical conditions such as aging, allergies, multiple trauma, rheumatoid arthritis, inflammatory bowel disease, chronic fatigue syndrome, and irritable syndrome. In addition, pathogens, antigens, and decay substances are introduced into the intestinal mucosa due to increased permeability of the intestinal mucosa or damage to the intestinal mucosa, leading to inflammatory reactions, and endotoxins flowing into the bloodstream, resulting in bacterial translocation and intestinal endotoxemia. It causes various inflammatory reactions and immune reactions.
이러한, 장누수증후군은, 특이한 증상 없이 다양하고 광범위하며 모호한 증상을 호소하게 된다. 구체적으로 여러 가지 질환에서 공통적으로 호소하는 증상을 갖고 있다는 점에서 특이점이 있다.Such leaky gut syndrome complains of various, extensive, and ambiguous symptoms without specific symptoms. Specifically, it has a peculiarity in that it has symptoms that complain in common in various diseases.
상기 장누수증후군을 일으키는 정확한 원인이 밝혀진 바는 없으나 현재까지 진통제로 쓰이는 비스테로이드성항염증제재(non-steroidal antiin ammatory drugs, NSAID)를 오래 쓴 경우, 항생제와 스테로이드를 쓴 경우, 항암요법으로 항암 화학요법이나 방사선 치료를 받은 경우, 장관 정상세균총의 조성의 변화가 초래 되었을 때, 곰팡이의 장관 내 번식, 과량의 음식의 섭취, 부패한 음식의 섭취나 중금속이나 독성물질을 섭취 했을 때, 지나치게 자극적인 음식물의 섭취나 특정음식물에 과민반응이 있는 경우, 알코올의 과량복용, 다발성 외상, 급 ㅇ 만성 정신적 스트레스에 노출 되었을 때나 만성적인 장관의 세균, 기생충, 이스트 등의 감염 등을 들 수 있다.The exact cause of the leaky gut syndrome has not been identified, but the use of non-steroidal antiin ammatory drugs (NSAIDs) used as pain relievers for a long time, antibiotics and steroids, anticancer chemistry as an anticancer therapy In the case of receiving therapy or radiation therapy, when a change in the composition of the normal intestinal flora occurs, the reproduction of fungi in the intestine, ingestion of excessive food, ingestion of spoiled food or ingestion of heavy metals or toxic substances, excessively irritating food Ingestion or hypersensitivity to certain foods, excessive use of alcohol, multiple trauma, exposure to acute chronic mental stress, chronic intestinal bacteria, parasites, and yeast infections can be cited.
구체적으로 상기 장누수증후군 개선, 예방 또는 치료용 조성물은 상기 다양한 원인에 의해 장관의 투과성이 증가되는 것을, 개선, 예방, 완화, 억제 및 치료하는 조성물이라고도 할 수 있다. 이는 장 투과성이 증가되어 혈액 내 고분자 물질이 장관내 관강으로 누수되거나 관강 내의 고분자 물질이 지접 혈액으로 들어가, 다양한 질환이 유발되는 장누수증후군을 개선, 예방, 치료하는 효과를 갖는다. 장누수증후군 개선, 예방 또는 치료란 장정막 세포 간극이 느슨해져 고분자 물질이 왕복할 수 있는 장점막 투과성이 증가되는 현상을 억제하는 것을 의미할 수 있다.Specifically, the composition for improving, preventing or treating leaky gut syndrome may be referred to as a composition for improving, preventing, alleviating, suppressing and treating that the permeability of the intestine is increased due to the various causes. This has the effect of improving, preventing, and treating intestinal leak syndrome, which causes various diseases, as high intestinal permeability increases, so that polymeric substances in the blood leak into the intestinal lumen, or polymeric substances in the lumen enter the branched blood. The improvement, prevention, or treatment of leaky gut syndrome may mean suppressing a phenomenon in which the intestinal membrane cell gap is loosened and thus the permeability of the intestinal membrane through which a polymer material can reciprocate increases.
상기 염증성 장질환은 크론병, 궤양성 대장염, 장형 베체트병, 감염성 장염, 허혈성 장질환 및 방사선 장염으로 이루어진 군에서 선택되는 질환일 수 있다.The inflammatory bowel disease may be a disease selected from the group consisting of Crohn's disease, ulcerative colitis, enteric Behcet's disease, infectious enteritis, ischemic bowel disease, and radiation enteritis.
본 발명의 실험결과에 의하면, 고지방 식이를 장기간 투여하였을 때, 사이토카인 IL-6와 같은 염증 인자가 증가되고, 염증 세포의 활성화가 증가하였음을 볼 수 있다. 이는 시간이 경과함에 따라 장내 염증을 유도하며, 곧 장염이 유도되게 된다.According to the experimental results of the present invention, it can be seen that when a high-fat diet is administered for a long time, inflammatory factors such as cytokine IL-6 are increased, and the activation of inflammatory cells is increased. This induces inflammation in the intestine over time, and soon enteritis is induced.
이때, 고춧잎 추출물을 병용투여하면 면역 활성은 증가되고, 염증 반응을 억제되며, 염증 세포의 활성화를 감소시키는 것을 확인할 수 있다. 따라서 본 발명에 따른 고춧잎 추출물을 유효성분으로 하는 조성물은 염증성 장질환 개선, 예방 또는 치료 효과를 가짐을 알 수 있다.At this time, it can be seen that when the red pepper leaf extract is co-administered, immune activity is increased, inflammatory response is suppressed, and activation of inflammatory cells is reduced. Therefore, it can be seen that the composition comprising the red pepper leaf extract according to the present invention as an active ingredient has an effect of improving, preventing or treating inflammatory bowel disease.
상기 고춧잎 추출물은 보다 구체적으로 IgA 발현을 증진시키고, IL-6의 발현과 LTB4 발현을 억제 또는 감소시키는 것을 특징으로 한다.The red pepper leaf extract is more specifically characterized in that it enhances IgA expression and inhibits or reduces the expression of IL-6 and LTB 4.
본 발명에서 '추출물'은 추출 원재료에 추출 용매를 처리하여 얻은 조추출물뿐만 아니라 조추출물의 가공물도 포함한다. 예를 들어, 고춧잎 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다. In the present invention, the'extract' includes not only the crude extract obtained by treating the extraction raw material with the extraction solvent, but also the processed product of the crude extract. For example, the red pepper leaf extract may be prepared in a powder state by additional processes such as distillation under reduced pressure and freeze drying or spray drying.
또한 본 발명에서 '추출물'은 상기 조추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다. 즉, 고춧잎 추출물은 추출 용매를 이용하여 얻은 것뿐만 아니라, 여기에 정제과정을 추가적으로 적용하여 얻은 것도 포함한다. 예를 들어, 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 고분자 분획물, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 방법을 통해 정제할 수 있다.In addition, the'extract' in the present invention also includes a fraction obtained by further fractionating the crude extract. That is, the red pepper leaf extract includes not only those obtained by using an extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, a polymer fraction obtained by passing through an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity), etc. It can be purified through a method.
상기 고분자 분획물은 바람직하게 고춧잎 추출물 또는 고춧잎 추출물을 추출 용매를 이용해 얻은 후, 분자량 10 kDa 이상의 고분자 물질만 분리해 놓은 분획물일 수 있다.The polymer fraction may preferably be a fraction obtained by separating only a polymer material having a molecular weight of 10 kDa or more after obtaining a red pepper leaf extract or a red pepper leaf extract using an extraction solvent.
또한 본 발명에서 '고춧잎 추출물'은 상기 고추 잎을 물, 탄소수 1 내지 4 개의 알코올 또는 이들의 혼합 용매에 의한 추출물로서, 추출방법은 특별히 한정할 필요가 없다. 바람직하게는 상기 고춧잎 추출물은 고춧잎 열수 추출물 또는 고춧잎 에탄올 수용액일 수 있으며, 예를 들어 고춧잎 주정 추출물일 수 있다. 가장 바람직하게는 고춧잎 열수 추출물일 수 있다.In addition, in the present invention, the'pepper leaf extract' is an extract of the red pepper leaf using water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof, and the extraction method does not need to be particularly limited. Preferably, the red pepper leaf extract may be a hot water extract of red pepper leaf or an ethanol solution of red pepper leaf, and may be, for example, a red pepper leaf alcohol extract. Most preferably, it may be a hot water extract of red pepper leaves.
또한, 상기 고춧잎 추출물은 상기 고춧잎 추출물을 가공하고, 이를 다시 물, 탄소수 1 내지 4 개의 알코올 또는 이들의 혼합 용매로 1회 이상 반복 추출한 것일 수 있다.In addition, the red pepper leaf extract may be processed by the red pepper leaf extract, and then repeatedly extracted one or more times with water, alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 고춧잎은 고추의 잎을 일정한 크기로 절단하여 그늘이나, 건조기를 사용하여 건조한 후, 파쇄시키거나 그대로 사용할 수 있다. 상기 건조 기간은 상기 고춧잎 내에 수분함량이 20% 미만인 것이라면 특별히 한정되지 않는다.The red pepper leaves may be cut into a certain size, dried using a shade or a dryer, and then crushed or used as it is. The drying period is not particularly limited as long as the moisture content in the red pepper leaves is less than 20%.
고추의 다른 부위에 비해 고추 잎을 사용한 것이, 고지방 식이를 장기간 투여하였을 때 IgA 발현을 증진시키고, IL-6의 발현과 LTB4 발현을 억제 또는 감소효과면에서 1.5~2.5 배 이상 높으며, 장투과성 역시 2~5배 이상 억제되므로, 고추의 다른 부위에 비해 고춧잎 추출물은 염증성 장질환뿐만 아니라 장누수증후군을 예방 또는 개선 또는 치료하는 효과가 현저히 우수하다.Compared to other parts of pepper, using pepper leaves increases IgA expression when administered on a high-fat diet for a long period of time , inhibits or reduces IL-6 expression and LTB 4 expression, and is 1.5 to 2.5 times higher in effect, and intestinal permeability. Since it is also suppressed by 2 to 5 times or more, red pepper leaf extract is remarkably excellent in preventing, improving, or treating inflammatory bowel disease as well as intestinal leak syndrome compared to other parts of pepper.
본 발명에서 '유효성분으로 하는' 또는 '유효성분으로 포함하는'이란 본 발명의 고춧잎 추출물의 염증성 장질환 또는 장누수증후군을 개선, 예방 또는 치료하는 데 충분한 양을 포함하는 것을 의미한다. 상기 고춧잎 추출물은 천연물로서 과량 투여하여도 인체에 부작용이 없으므로 본 발명의 조성물 내에 포함되는 고춧잎 추출물의 양적 상한 및 하한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.In the present invention, the term "contained as an active ingredient" or "contained as an active ingredient" means including an amount sufficient to improve, prevent or treat inflammatory bowel disease or leaky intestinal syndrome of the red pepper leaf extract of the present invention. Since the red pepper leaf extract is a natural product and does not have side effects on the human body even if it is administered in an excessive amount, the upper and lower limits of the quantity of the red pepper leaf extract included in the composition of the present invention can be selected and carried out by a person skilled in the art within an appropriate range.
본 발명에서는, 상기 고춧잎 추출물을 유효성분으로 함유하는 조성물을 처리하였을 때, 상기 조성물이 고지방 식이를 장기간 투여하였을 때 IgA 발현을 증진시키고, IL-6의 발현과 LTB4 발현을 억제 또는 감소시켜, 염증성 장질환을 예방 또는 개선 또는 치료하는 효과가 있음을 확인하였고, 장투과성을 억제 및 감소시키는 효과가 있음을 확인하였다.In the present invention, when the composition containing the red pepper leaf extract as an active ingredient is treated, the composition enhances IgA expression when administered on a high fat diet for a long period of time, and inhibits or reduces the expression of IL-6 and LTB 4, It was confirmed that there is an effect of preventing, improving or treating inflammatory bowel disease, and it was confirmed that it has an effect of inhibiting and reducing intestinal permeability.
본 발명의 조성물은 식품 조성물로, 본 발명의 고춧잎 추출물을 유효성분으로 하는 염증성 장질환 또는 장누수증후군 개선, 예방용 식품 조성물로 다양하게 이용될 수 있다. The composition of the present invention may be variously used as a food composition for improving and preventing inflammatory bowel disease or leaky intestinal syndrome using the red pepper leaf extract of the present invention as an active ingredient.
본 발명에 따른 식품 조성물은 후술하는 하기 약학 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 알코올 음료류, 과자류, 다이어트바, 유제품, 육류, 초코렛, 피자, 라면, 기타 면류, 껌류, 아이스크림류, 비타민 복합제, 건강보조식품류 등이 있다.The food composition according to the present invention may be formulated in the same manner as the pharmaceutical composition described below to be used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectionery, diet bars, dairy products, meat, chocolate, pizza, ramen, other noodles, gums, ice creams, vitamin complexes, health supplements. Etc.
본 발명의 식품 조성물은 유효성분으로서 고춧잎 추출물뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제와 음료류로 제조되는 경우에는 본 발명의 고춧잎 추출물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 및 각종 식물 추출액 등을 추가로 포함시킬 수 있다.The food composition of the present invention may include not only red pepper leaf extract as an active ingredient, but also ingredients commonly added during food production, for example, proteins, carbohydrates, fats, nutrients, flavoring agents, and flavoring agents. Examples of the aforementioned carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides, and the like; And polysaccharides, for example, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents, natural flavoring agents [taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.]) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is made of drinks and beverages, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts, etc., in addition to the red pepper leaf extract of the present invention may be further included.
본 발명은 상기 고춧잎 추출물을 유효성분으로 포함하는 염증성 장질환 또는 장누수증후군 개선, 억제 또는 예방용 식품 조성물을 포함하는 건강기능식품을 제공한다. 건강기능식품이란, 고춧잎 추출물을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용시 발생할 수 있는 부작용 등이 없는 장점이 있다. 이와 같이 하여 얻어지는 본 발명의 건강기능식품은, 일상적으로 섭취하는 것이 가능하기 때문에 매우 유용하다. 이와 같은 건강기능식품에 있어서의 고춧잎 추출물의 첨가량은, 대상인 건강기능식품의 종류에 따라 달라 일률적으로 규정할 수 없지만, 식품 본래의 맛을 손상시키지 않는 범위에서 첨가하면 되며, 대상 식품에 대하여 통상 0.01 내지 50 중량%, 바람직하기로는 0.1 내지 20 중량%의 범위이다. 또한, 환제, 과립제, 정제 또는 캡슐제 형태의 건강기능식품의 경우에는 통상 0.1 내지 100 중량% 바람직하기로는 0.5 내지 80 중량%의 범위에서 첨가하면 된다. 한 구체예에서, 본 발명의 건강기능식품은 환제, 정제, 캡슐제 또는 음료의 형태일 수 있다.The present invention provides a health functional food comprising a food composition for improving, inhibiting or preventing inflammatory bowel disease or leaky gut syndrome comprising the red pepper leaf extract as an active ingredient. Health functional foods are foods prepared by adding red pepper leaf extract to food ingredients such as beverages, teas, spices, chewing gums, confectionery, etc., or prepared by encapsulation, powdering, or suspension. However, unlike general drugs, it has the advantage of not having side effects that may occur when taking drugs for a long time by using food as a raw material. The health functional food of the present invention obtained in this way is very useful because it can be consumed on a daily basis. The amount of red pepper leaf extract added in such health functional foods cannot be uniformly regulated depending on the type of health functional food to be targeted, but it can be added within the range that does not damage the original taste of the food, and is usually 0.01 for the target food. To 50% by weight, preferably 0.1 to 20% by weight. In addition, in the case of health functional foods in the form of pills, granules, tablets or capsules, it is usually added in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.
또 다른 예에서 상기한 바와 같이 고춧잎 추출물을 유효성분으로 하는 염증성 장질환 또는 장누수증후군 예방 또는 치료용 약학 조성물로 이용될 수 있다. 유효성분인 고춧잎 추출물 외에 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.In another example, as described above, it may be used as a pharmaceutical composition for preventing or treating inflammatory bowel disease or leaky intestinal syndrome using red pepper leaf extract as an active ingredient. In addition to the red pepper leaf extract, which is an active ingredient, it can be prepared using a pharmaceutically suitable and physiologically acceptable auxiliary agent, and the auxiliary agent includes excipients, disintegrants, sweeteners, binders, coating agents, expanding agents, lubricants, lubricants or flavoring agents. Etc. can be used.
상기 약학 조성물은 투여를 위해서 상기 기재한 유효 성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 약학 조성물로 바람직하게 제제화할 수 있다.For administration, the pharmaceutical composition may contain one or more pharmaceutically acceptable carriers in addition to the above-described active ingredients, and may be preferably formulated into a pharmaceutical composition.
상기 약학 조성물의 제제 형태는 과립제, 산제, 정제, 피복정, 캡슐제, 좌제, 액제, 시럽, 즙, 현탁제, 유제, 점적제 또는 주사 가능한 액제 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다.The formulation form of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops, or injectable solutions. For example, for formulation in the form of a tablet or capsule, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. In addition, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture. Suitable binders are, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, trackcacanth or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
액상 용액으로 제제화되는 조성물에 있어서 허용 가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다.Acceptable pharmaceutical carriers for compositions formulated as liquid solutions are sterilized and biocompatible, and include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as necessary. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to prepare injection formulations such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or tablets.
더 나아가 해당분야의 적절한 방법으로 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화할 수 있다.Further, it can be preferably formulated according to each disease or ingredient using a method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
본 발명의 약학 조성물은 경구 또는 비경구로 투여할 수 있고, 비경구 투여인 경우에는 정맥내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있으며, 바람직하게는 경구 투여이다.The pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., preferably oral administration.
본 발명의 약학 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망하는 치료 또는 예방에 효과적인 투여량을 용이하게 결정 및 처방할 수 있다. 본 발명의 바람직한 구현예에 따르면, 본 발명의 약학 조성물의 1일 투여량은 0.001-10 g/㎏이다.A suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, mode of administration, age, weight, sex, pathological condition, food, administration time, route of administration, excretion rate and response sensitivity of the patient, and is usually As such, a skilled physician can easily determine and prescribe an effective dosage for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g/kg.
본 발명의 약학 조성물은 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention may be prepared in unit dosage form by formulation using a pharmaceutically acceptable carrier and/or excipient, or may be prepared by incorporating it into a multi-dose container. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet or capsule, and may additionally include a dispersant or a stabilizer.
또한, 본 발명은 포유동물에게 유효량의 고춧잎 추출물을 투여하는 것을 포함하는 염증성 장질환 또는 장누수증후군의 개선, 예방 또는 치료 방법을 제공한다.In addition, the present invention provides a method for improving, preventing or treating inflammatory bowel disease or leaky intestinal syndrome comprising administering an effective amount of red pepper leaf extract to a mammal.
여기에서 사용된 용어 "포유동물"은 치료, 관찰 또는 실험의 대상인 포유동물을 말하며, 바람직하게는 인간을 말한다.The term "mammal" as used herein refers to a mammal that is an object of treatment, observation or experiment, and preferably refers to a human.
여기에서 사용된 용어 "유효량"은 연구자, 수의사, 의사 또는 기타 임상의에 의해 생각되는 조직계, 동물 또는 인간에서 생물학적 또는 의학적 반응을 유도하는 유효 성분 또는 약학 조성물의 양을 의미하는 것으로, 이는 해당 증상의 완화를 유도하는 양을 포함한다. 본 발명의 유효성분에 대한 유효량 및 투여횟수는 원하는 효과에 따라 변화될 수 있다. 그러므로, 투여될 최적의 투여량은 당업자에 의해 쉽게 결정될 수 있으며, 염증성 장질환의 증상 정도, 장누수증후군에 대한 장투과성 정도, 조성물에 함유된 유효성분 및 다른 성분의 함량, 제형의 종류, 및 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료기간, 동시 사용되는 약물을 비롯한 다양한 인자에 따라 조절될 수 있다. 본 발명의 예방, 치료 또는 개선 방법에 있어서, 성인의 경우, 고춧잎 추출물을 1일 1회 내지 수회 투여시, 0.001 g/㎏ 내지 10 g/㎏의 용량으로 투여하는 것이 바람직하다.The term "effective amount" as used herein refers to an amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, which is considered by a researcher, veterinarian, doctor or other clinician, which Contains an amount that induces the alleviation of. The effective amount and the number of administrations for the active ingredient of the present invention may be changed according to the desired effect. Therefore, the optimal dosage to be administered can be easily determined by those skilled in the art, and the degree of symptoms of inflammatory bowel disease, the degree of intestinal permeability to leaky intestinal syndrome, the content of active ingredients and other ingredients contained in the composition, the type of formulation, and It can be adjusted according to various factors, including the age, weight, general health status, sex and diet of the patient, the time of administration, the route of administration and the secretion rate of the composition, the treatment period, and drugs used simultaneously. In the prophylaxis, treatment or improvement method of the present invention, in the case of an adult, it is preferable to administer the red pepper leaf extract at a dose of 0.001 g/kg to 10 g/kg when administered once to several times a day.
본 발명의 치료방법에서 고춧잎 추출물을 유효성분으로 포함하는 조성물은 경구, 직장, 정맥내, 동맥내, 복강내, 근육내, 흉골내, 경피, 국소, 안구내 또는 피내 경로를 통해 통상적인 방식으로 투여할 수 있고, 바람직하는 경구, 복강 내에 투여할 수 있다.In the treatment method of the present invention, the composition containing the red pepper leaf extract as an active ingredient is in a conventional manner through oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, topical, intraocular or intradermal routes. It can be administered, and can be preferably administered orally or intraperitoneally.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범주 및 기술사상 범위 내에서 다양한 변경 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속하는 것도 당연한 것이다.Hereinafter, a preferred embodiment is presented to aid in the understanding of the present invention, but it is obvious to those skilled in the art that various changes and modifications are possible within the scope of the present invention and the scope of the technical idea, but the following examples are only illustrative of the present invention, It is natural that such modifications and modifications fall within the scope of the appended claims.
실시예 1. 고춧잎 열수 추출물Example 1. Hot water extract of red pepper leaves
경북예천농협에서 생산한 국내산 건조 고춧잎을 구매하여 사용하였다. 고춧잎을 50 ℃ 건조 오븐에서 24시간 건조한 다음 분쇄기로 1.0 ㎜ 이하가 되도록 분쇄하여 고춧잎 분말을 준비하였다.Dried domestic red pepper leaves produced by Yecheon Nonghyup in Gyeongbuk were purchased and used. Red pepper leaves were dried in a drying oven at 50° C. for 24 hours, and then pulverized to a size of 1.0 mm or less with a grinder to prepare red pepper leaf powder.
고춧잎 분말 5 g에 20 배 부피에 해당하는 증류수를 가하고 80 ℃ 에서 3 시간 동안 환류 추출하여 열수 추출물을 수득하였다. 상기 열수 추출물을 여과한 후, 회전 진공 증발기(rotary vacuum evaporator)를 이용하여 감압농축하고, 72 시간 동안 동결건조하였다. 상기 방법으로 수득한 고춧잎 열수 추출물은 WEPL(Water-soluble extract from pepper leaves)로 기재하였다.Distilled water equivalent to 20 times the volume was added to 5 g of red pepper leaf powder, followed by reflux extraction at 80° C. for 3 hours to obtain a hot water extract. After filtering the hot water extract, it was concentrated under reduced pressure using a rotary vacuum evaporator, and lyophilized for 72 hours. The hot water extract of pepper leaves obtained by the above method was described as WEPL (Water-soluble extract from pepper leaves).
실시예 2. 고춧잎 고분자 분획물Example 2. Red pepper leaf polymer fraction
경북예천농협에서 생산한 국내산 건조 고춧잎을 구매하여 사용하였다. 고춧잎을 50 ℃ 건조 오븐에서 24시간 건조한 다음 분쇄기로 1.0 ㎜ 이하가 되도록 분쇄하여 고춧잎 분말을 준비하였다.Dried domestic red pepper leaves produced by Yecheon Nonghyup in Gyeongbuk were purchased and used. Red pepper leaves were dried in a drying oven at 50° C. for 24 hours, and then pulverized to a size of 1.0 mm or less with a grinder to prepare red pepper leaf powder.
고춧잎 분말 100 g에 20 배 부피에 해당하는 증류수를 가하고 80 ℃의 온도에서 3 시간 동안 환류 추출하여 열수 추출물을 수득하였다. 상기 열수 추출물을 여과한 다음, 회전 진공 증발기(rotary vacuum evaporator)를 이용하여 추출액의 1/10이 되도록 감압농축하고, 감압농축된 열수 추출물의 4배 부피(v/v)에 해당하는 80% 주정을 상기 열수 추출물에 가하여 24시간 침전시켰다. 이를 원심분리(6000 rpm, 635ㅧg, 30분)하여 침전물을 얻었으며 여기에 소량의 증류수를 가하여 침전물을 재용해하고 투석막(MW cut off 12,000, Sigma-Aldrich Co., St. Louis, MO, USA)을 이용하여 2~3일간 투석을 행하여 저분자물질을 제거하였으며 72 시간 동결건조하여, 고춧잎 고분자 분획물을 얻었다. 상기 방법으로 수득한 고춧잎 고분자 분획물은 HFPL(High-molecular fraction from pepper leaves)라고 명명하였다.Distilled water equivalent to 20 times the volume was added to 100 g of red pepper leaf powder, followed by reflux extraction at 80° C. for 3 hours to obtain a hot water extract. After filtering the hot water extract, it is concentrated under reduced pressure to be 1/10 of the extract using a rotary vacuum evaporator, and 80% alcohol corresponding to 4 times the volume (v/v) of the hot water extract concentrated under reduced pressure Was added to the hot water extract and precipitated for 24 hours. This was centrifuged (6000 rpm, 635 g, 30 minutes) to obtain a precipitate. A small amount of distilled water was added thereto to redissolve the precipitate and a dialysis membrane (MW cut off 12,000, Sigma-Aldrich Co., St. Louis, MO, USA) was performed for 2 to 3 days to remove low molecular weight substances, and freeze-dried for 72 hours to obtain a polymer fraction of red pepper leaves. The red pepper leaf polymer fraction obtained by the above method was named HFPL (High-molecular fraction from pepper leaves).
비교예 1. 가르시니아 캄보지아 추출물Comparative Example 1. Garcinia cambogia extract
가르시니아 캄보지아 추출물은 인도 Unicon Natural Products PVT사로부터 구매하여 사용하였다. 이때, 상기 가르시니아 캄보지아 추출물은 HCA을 600 mg/g 이상으로 함유하는 것을 사용하였다.Garcinia cambogia extract was purchased and used from Unicon Natural Products PVT, India. At this time, the garcinia cambogia extract was used that contains 600 mg/g or more of HCA.
<시험예><Test Example>
시험예 1. 실시예 1의 고춧잎 열수 추출물 및 실시예 2의 고춧잎 고분자 분획물의 수율, 당과 단백질 함량 분석Test Example 1. Analysis of yield, sugar and protein content of hot water extract of red pepper leaf of Example 1 and polymer fraction of red pepper leaf of Example 2
중성당 분석은 Albersheim 등의 방법을 일부 변형하여 가수분해 후 각 구성당을 알디톨 아세테이트(alditol acetate)와 aldonolactone로 유도체화 하여 GC(Gas Chromatography ACME-6100, Young-Lin Co. Ltd. Anyang, Korea)를 이용하여 분석하였다. 실시예 1 또는 실시예 2의 시료를 2 M TFA(trifluroacetic acid) 중에서 121℃, 1.5 hr 반응시켜 가수분해한 후, 1 ㎖의 1 M NH4OH (ammonia solution)에 용해하여 10 ㎎의 NaBH4로 4 hr 환원시켰다. Acetic acid를 적당량 가하여 잔존 NaBH4를 제거한 후, 메탄올을 가하며 반복 건조함으로써 과량으로 가해진 아세트산을 제거하여 알디톨(alditol)로 전환하였다. 상기 알디톨(alditol)에 1 ㎖의 아세트산 무수물(acetic anhydride)을 가하여 121℃에서 30 min 동안 반응시켜 알디톨 아세테이트(alditol acetate)로 전환시켰으며 이를 클로로포름/H2O 2상 용매계로 분리하여 추출하고, 추출물은 건조 후 소량의 아세톤에 용해하여 GC 분석용 시료로 사용하였다.For the analysis of neutral sugars, the method of Albersheim et al. was partially modified to derivatize each constituent sugar with alditol acetate and aldonolactone after hydrolysis, and GC (Gas Chromatography ACME-6100, Young-Lin Co. Ltd. Anyang, Korea) ) Was used. The sample of Example 1 or 2 was hydrolyzed by reacting for 1.5 hr at 121° C. in 2 M TFA (trifluroacetic acid), and then dissolved in 1 ml of 1 M NH 4 OH (ammonia solution) and 10 mg of NaBH 4 It was reduced by 4 hr. After adding an appropriate amount of acetic acid to remove the remaining NaBH 4 , methanol was added thereto and repeated drying to remove excess acetic acid and converted to alditol. 1 ml of acetic anhydride was added to the alditol and reacted at 121° C. for 30 min to convert to alditol acetate, which was separated and extracted with a chloroform/H 2 O two-phase solvent system. After drying, the extract was dissolved in a small amount of acetone and used as a sample for GC analysis.
단백질 정량은 Bradford법에 따라 측정하였으며, BSA(Bovine Serum Albumin, sigma aldrich)를 표준품으로 사용하여 1 ㎎/㎖를 최고 농도로 하여 일정배수로 희석하였다. Bradford시약 980 ㎕에 표준품과 시료를 각각 20 ㎕를 가하여 반응시킨 후 microplate reader를 이용하여 595 nm에서 흡광도를 측정하였다. 단백질 정량은 BSA에 대한 양으로 환산하였다.Protein quantification was measured according to the Bradford method, and BSA (Bovine Serum Albumin, sigma aldrich) was used as a standard and diluted at a constant multiple with 1 mg/ml as the highest concentration. After adding 20 µl of each standard and sample to 980 µl of Bradford reagent, the absorbance was measured at 595 nm using a microplate reader. Protein quantification was converted into an amount for BSA.
총당은 phenol-sulfuric acid법에 따라 측정하였으며, 시료용액 0.5 mL에 동량의 5 % phenol 용액을 첨가하여 교반한 후 진한 황산(98%, v/v) 2.5 mL를 가하여 상온에서 20분간 반응시켜 microplate reader를 이용하여 470 nm에서 흡광도를 측정하였다. 총당의 정량은 glucose 표준품(sigma aldrich)을 사용하여 검량선을 작성하여 이에 대한 양으로 환산하였다.Total sugar was measured according to the phenol-sulfuric acid method, and after stirring the same amount of 5% phenol solution to 0.5 mL of the sample solution, 2.5 mL of concentrated sulfuric acid (98%, v/v) was added and reacted at room temperature for 20 minutes to make a microplate. Absorbance was measured at 470 nm using a reader. For the determination of total sugar, a calibration curve was prepared using a glucose standard (sigma aldrich) and converted into the amount.
총 폴리페놀 함량은 gallic acid(sigma aldrich)를 이용하여 Folin Denis법에 따라 분석하였다.The total polyphenol content was analyzed according to the Folin Denis method using gallic acid (sigma aldrich).
구성당의 경우, 시료의 당사슬을 단당으로 가수분해 한 후 HPAEC-PAD(high-performance anion-exchange chromatography-pulsed amperometric detector)를 사용하였으며, 데이터는 Chromelon 6.80 소프트웨어 (Dionex)를 이용하여 분석하였다. 표준용액으로 단당류(fucose, rhamnose, arabinose, galactose, glucose, xylose)를 사용하였다. In the case of constituent sugar, the oligosaccharides of the sample were hydrolyzed to monosaccharides, and then HPAEC-PAD (high-performance anion-exchange chromatography-pulsed amperometric detector) was used, and the data were analyzed using Chromelon 6.80 software (Dionex). Monosaccharides (fucose, rhamnose, arabinose, galactose, glucose, xylose) were used as standard solutions.
그 결과, 고춧잎으로부터 열수 추출물 및 고분자 분획물의 주요성분 함량 등의 이화확적 특성을 분석한 결과 하기 표 1과 같았다.As a result, as a result of analyzing the physicochemical properties such as the content of main components of the hot water extract and the polymer fraction from red pepper leaves, it is shown in Table 1 below.
* 상기 chemical component의 함량비(%)는 건조 샘플 내의 중량%를 나타낸 것이다.* The content ratio (%) of the chemical component represents the weight% in the dry sample.
표 1에 나타난 바와 같이, 실시예 1로부터 제조된 고춧잎 열수 추출물은 수율이 12.66%로 나타났으며, 단백질 함량은 4.5 중량%, 중성당 함량은 70.7 중량%로 당함량이 높은 것으로 확인되었다. 또한, 실시예 1로부터 제조된 고춧잎 열수 추출물의 구성당을 분석한 결과, 주요 구성당은 glucose(54.8 Mole %)였고, galacturonic acid, rhamnose, galactose가 각각 11.1, 9.3, 8.5 Mole %로 함유되어 있었으며, arabionose, mannose, xylose가 각각 2.5, 0.8, 0.6 Mole %로 미량 존재하고 있음을 확인하였다.As shown in Table 1, the hot water extract of red pepper leaves prepared from Example 1 was found to have a yield of 12.66%, a protein content of 4.5% by weight, and a neutral sugar content of 70.7% by weight, indicating a high sugar content. In addition, as a result of analyzing the constituent sugars of the hot water extract of red pepper leaves prepared in Example 1, the main constituent sugar was glucose (54.8 Mole%), and galacturonic acid, rhamnose, and galactose were contained in 11.1, 9.3, and 8.5 Mole%, respectively. , arabionose, mannose, and xylose were found to be present in trace amounts of 2.5, 0.8, 0.6 Mole%, respectively.
이에 반해, 실시예 2로부터 제조된 고춧잎 고분자 분획물의 수율은 2.68%로 낮게 나타났으나, 단백질 함량이 4.3 중량%, 중성당 함량이 52.4 중량%, 우론산이 36.7 중량%인 것으로 확인되었다. 또한 실시예 2로부터 제조된 고춧잎 고분자 분획물에서 구성당 함량은 galacturonic acid, glucose가 각각 36.0, 34.6 Mole %로 검출되었고, galactose, arabinose, rhamnose, glucuronic acid, mannose, xylose, fucose가 각각 7.1, 4.9, 3.6, 1.5, 0.8, 0.6, 0.2 Mole %로 미량 존재하고 있음을 확인하였다. 실시예 2의 고춧잎 고분자 분획물(HEPL)은 당함량이 실시예 1의 고춧잎 열수 추출물에 비해 전체적으로 감소하였으나, Arabinose, Fucose, Glucuronic acid의 함량은 소폭 증가하는 것을 확인하였다. 즉 두 추출물 내에 존재하는 구체적인 구성성분 상에 분명한 차이가 있음을 알 수 있다.On the other hand, the yield of the red pepper leaf polymer fraction prepared from Example 2 was found to be as low as 2.68%, but it was confirmed that the protein content was 4.3% by weight, the neutral sugar content was 52.4% by weight, and the uronic acid was 36.7% by weight. In addition, in the red pepper leaf polymer fraction prepared from Example 2, the constituent sugar content of galacturonic acid and glucose was detected as 36.0 and 34.6 Mole%, respectively, and galactose, arabinose, rhamnose, glucuronic acid, mannose, xylose, and fucose were 7.1, 4.9, respectively. It was confirmed that there were trace amounts of 3.6, 1.5, 0.8, 0.6, and 0.2 Mole %. It was confirmed that the sugar content of the red pepper leaf polymer fraction (HEPL) of Example 2 was reduced as a whole compared to the hot water extract of red pepper leaf of Example 1, but the contents of Arabinose, Fucose, and Glucuronic acid slightly increased. That is, it can be seen that there is a clear difference between the specific components present in the two extracts.
시험예 2. 실시예 1의 고춧잎 열수 추출물의 염증 관련 인자 분석Test Example 2. Analysis of Factors Related to Inflammation of Hot Water Extract of Red Pepper Leaf of Example 1
1) 실험동물1) Experimental animals
우선, 6주령의 수컷 C57BL/6J mouse 45 마리를 중앙실험동물을 통해 구입하였다. 상기 실험동물은 다음과 같이 다섯 그룹으로 분리하였다. 각 그룹당 9마리의 실험동물을 사용하였고, 8주간의 식이를 진행한 후 장관 면역 조절 효능을 평가하였다.First, 45 6-week-old male C57BL/6J mice were purchased through a central laboratory animal. The experimental animals were divided into five groups as follows. Nine experimental animals were used for each group, and after 8 weeks of diet, the intestinal immune modulating efficacy was evaluated.
- 정상 사료군(NC): 정상 사료(AIN-93G)를 먹이고, vehicle만을 경구투여 한 실험군-Normal feed group (NC): An experimental group fed with normal feed (AIN-93G) and administered only the vehicle orally
- 고지방 식이군(HFD): 고지방(60% kcal fat) 사료를 먹이고, vehicle만을 경구투여 한 실험군-High fat diet group (HFD): Experimental group that fed high fat (60% kcal fat) feed and administered only vehicle orally
- 양성 대조군(GC): 고지방 사료를 먹이고, 가르시니아 캄보지아 추출물 50 ㎎/㎏을 경구투여 한 실험군-Positive control group (GC): An experimental group fed with a high-fat feed and orally administered 50 mg/kg of garcinia cambogia extract
- 제1실험군(WEPL50): 고지방 사료를 먹이고, 실시예 1로부터 제조된 고춧잎 열수 추출물 50 ㎎/㎏을 경구투여 한 실험군-Experimental group 1 (WEPL50): an experimental group in which 50 mg/kg of hot water extract of red pepper leaves prepared in Example 1 was orally administered after feeding a high-fat feed
- 제실험군(WEPL100): 고지방 사료를 먹이고, 실시예 1로부터 제조된 고춧잎 열수 추출물 100 ㎎/㎏을 경구투여 한 실험군으로 구성하였다. -Experimental group (WEPL100): A high-fat feed was fed, and 100 mg/kg of hot water extract of red pepper leaves prepared in Example 1 was administered orally.
이때, 고지방 사료는 Lard를 첨가하여 열량을 60 cal%를 증가시킨 Modified AIN 76A purified rodent diet(60 cal% fat)를 사용하였다.At this time, a modified AIN 76A purified rodent diet (60 cal% fat) was used as a high fat diet, which increased calorie by 60 cal% by adding Lard.
2) 분석2) analysis
8주의 식이 기간이 끝나고, 분석하기 6시간 전부터 각 그룹의 실험동물을 절식시켰다. 다음, 실험동믈을 마취시키고 복부를 개복하였다. 멸균 주사기를 사용하여 하대정맥에서 채혈한 후, 헤파린으로 처리된 멸균튜브에 보관하였다. 수득한 혈액은 원심분리(12,000 ×g, 10분, 4℃)하여 상등액을 취해 분석에 사용하였다. 혈중 immunoglobulin A, IL-6, leukotriene B4 농도는 각각 Mouse IgA ELISA kit(Abcam, ab157717), Mouse IL-6 Quantikine ELISA kit(R&D systems, M6000B), LTB4 Parameter Assay Kit(R&D systems, KGE006B)를 이용하여 정량하였다. After the 8-week diet period was over, the experimental animals of each group were fasted from 6 hours before analysis. Next, the experimental animals were anesthetized and the abdomen was opened. After collecting blood from the inferior vena cava using a sterile syringe, it was stored in a sterile tube treated with heparin. The obtained blood was centrifuged (12,000 × g, 10 minutes, 4° C.), and the supernatant was taken and used for analysis. The concentrations of immunoglobulin A, IL-6, and leukotriene B4 in blood were determined using Mouse IgA ELISA kit (Abcam, ab157717), Mouse IL-6 Quantikine ELISA kit (R&D systems, M6000B), LTB4 Parameter Assay Kit (R&D systems, KGE006B), respectively. Quantified.
3) 분석결과3) Analysis result
실시예 1로부터 제조된 고춧잎 열수 추출물에 대한 장내 염증 관련 지표를 확인하였고, 그 결과를 도 1 내지 3에 나타내었다.Intestinal inflammation-related indicators for the hot water extract of red pepper leaves prepared from Example 1 were confirmed, and the results are shown in FIGS. 1 to 3.
도 1은 정상 사료군(NC), 양성 대조군(GC), 제1실험군(WEPL50) 및 제2실험군(WEPL100)에 대한 혈청 내 IgA의 농도를 측정하여 나타낸 그래프이다. 도 1에 나타난 바와 같이, 정상 사료군(NC)에서는 혈중 IgA 농도가 16.25 ㎍/㎖이였으나, 양성 대조군(GC)에서는 26.17 ㎍/㎖로 장내 면역 활성이 증진된 것을 확인하였다. 실시예 1로부터 제조된 고춧잎 열수 추출물을 50 ㎎/㎏ 농도로 경구 투여한 제1실험군에서는 25.52 ㎍/㎖의 IgA가 확인되었다. 또한 실시예 1로부터 제조된 고춧잎 열수 추출물을 100 ㎎/㎏ 농도로 경구 투여한 제2실험군에서는 30.91 ㎍/㎖ IgA가 검출되었다. 1 is a graph showing the measurement of the concentration of IgA in serum for the normal feed group (NC), the positive control group (GC), the first experimental group (WEPL50), and the second experimental group (WEPL100). As shown in FIG. 1, in the normal feed group (NC), the blood IgA concentration was 16.25 µg/ml, but in the positive control group (GC), it was confirmed that the intestinal immunity activity was increased to 26.17 µg/ml. In the first experimental group in which the hot water extract of red pepper leaves prepared in Example 1 was orally administered at a concentration of 50 mg/kg, 25.52 µg/ml of IgA was confirmed. In addition, 30.91 µg/ml IgA was detected in the second experimental group in which the hot water extract of red pepper leaves prepared in Example 1 was orally administered at a concentration of 100 mg/kg.
종합하면, 실시예 1의 고춧잎 열수 추출물 역시 양성 대조군(GC)와 같이 장내 면역활성을 증진시키고 있음을 알 수 있다. 특히, 고춧잎 열수 추출물(실시예 1)의 투여 농도가 증가할수록 장내 면역활성 또한 증가하고 있음을 확인한 바, 본 발명에 따른 고춧잎 열수 추출물은 장내 면역활성을 증진시켜 염증을 감소시키는 효과가 있음을 알 수 있다.Taken together, it can be seen that the hot water extract of red pepper leaves of Example 1 also enhances intestinal immune activity like the positive control (GC). In particular, it was confirmed that the intestinal immunity activity was also increased as the dose concentration of the hot water extract of red pepper leaves (Example 1) increased, and it was found that the hot water extract of red pepper leaves according to the present invention has the effect of reducing inflammation by enhancing intestinal immunity. I can.
도 2는 정상 사료군(NC), 고지방 식이군(HF), 양성 대조군(GC), 제1실험군(WEPL50) 및 제2실험군(WEPL100)에 대한 혈청 내 사이토카인 IL-6 발현양을 측정하여 나타낸 그래프이다. Figure 2 is by measuring the expression level of the cytokine IL-6 in serum for the normal feed group (NC), high fat diet group (HF), positive control group (GC), the first experimental group (WEPL50), and the second experimental group (WEPL100). This is the graph shown.
IL-6은 염증성 장질환에서 증가한다고 알려진 대표적인 사이토카인이다. 본 발명에서는 8주간의 장기적인 고지방 식이를 통해 염증성 장질환을 유도하는 한편, 실시예 1의 고춧잎 열수 추출물을 혼합 투여하여 염증성 장질환의 예방 또는 치료 효과를 살펴보고자 하였다. 도 2에 나타난 바와 같이, 8주간의 고지방 식이를 통해 염증성 장질환이 유도된 고지방 식이군(HF)은 12.37 pg/㎖로 IL-6의 농도가 크게 증가하였음을 알 수 있다. 고지방 식이와 실시예 1의 고춧잎 열수 추출물을 다양한 농도로 병용 투여한 제1, 제2실험군의 경우, 각각 1.78 pg/㎖과 1.96 pg/㎖의 IL-6이 검출되었다. 이는 염증성 장질환에 치료효과가 있는 것으로 알려진 가르시니아 캄보지아 추출물을 병용 투여한 양성 대조군(GC)에서의 IL-6(2.89 pg/㎖) 농도와 정상 사료군(NC)(2.78 pg/㎖)보다도 낮은 수치이다. 즉, 실시예 1로부터 제조된 고춧잎 열수 추출물은 정상 사료군 또는 가르시니아 캄보지아 추출물보다 IL-6 생성을 현저히 억제시키는 것을 알 수 있다. 이를 통해 본 발명에 따른 고춧잎 열수 추출물은 장내 염증반응을 억제하여 염증성 장질환에 대한 개선, 예방 또는 치료효과를 가지고 있음을 알 수 있다. 가르시니아 캄보지아의 경우 섭취시 구강건조증, 현기증, 두통 또는 설사 등의 다양한 부작용을 동반하는 것으로 알려져 있지만, 본 발명에 따른 고춧잎 열수 추출물은 일상적으로 섭취가능한 식품으로써 알려진 부작용이 없을뿐만 아니라 세포 독성 실험에서도 전혀 독성이 검출되지 않은 안정한 물질이라는 점에서 큰 강점을 갖는다.IL-6 is a representative cytokine known to be increased in inflammatory bowel disease. In the present invention, while inducing inflammatory bowel disease through a long-term high-fat diet for 8 weeks, the hot water extract of red pepper leaves of Example 1 was mixed and administered to investigate the effect of preventing or treating inflammatory bowel disease. As shown in Figure 2, it can be seen that the concentration of IL-6 was significantly increased to 12.37 pg/ml in the high fat diet group (HF) in which inflammatory bowel disease was induced through a high fat diet for 8 weeks. In the case of the first and second experimental groups in which the high-fat diet and hot water extract of red pepper leaf of Example 1 were co-administered at various concentrations, 1.78 pg/ml and 1.96 pg/ml of IL-6 were detected, respectively. This is lower than the concentration of IL-6 (2.89 pg/ml) in the positive control group (GC), which was co-administered with Garcinia cambogia extract, which is known to have a therapeutic effect on inflammatory bowel disease, and lower than that of the normal feed group (NC) (2.78 pg/ml). It's a shame. That is, it can be seen that the hot water extract of red pepper leaves prepared in Example 1 significantly inhibits IL-6 production than the normal feed group or garcinia cambogia extract. Through this, it can be seen that the hot water extract of red pepper leaves according to the present invention has an improvement, prevention or treatment effect for inflammatory bowel disease by suppressing the inflammatory reaction in the intestine. Garcinia cambogia is known to accompany various side effects such as dry mouth, dizziness, headache or diarrhea when ingested. It has a great advantage in that it is a stable substance with no toxicity detected.
도 3은 정상 사료군(NC), 고지방 식이군(HF), 양성 대조군(GC), 제1실험군(WEPL50) 및 제2실험군(WEPL100)에 대한 혈청 내 사이토카인 leukotriene B4(LTB4) 발현양을 측정하여 나타낸 그래프이다.Figure 3 is a normal feed group (NC), high fat diet group (HF), positive control group (GC), the first experimental group (WEPL50) and the second experimental group (WEPL100) in serum cytokine leukotriene B4 (LTB 4 ) expression amount It is a graph showing by measuring.
leukotriene B4(LTB4)는 면역세포에서 염증반응을 유발하여 염증성 세포의 활성에 관여하는 것으로 알려져 있다. 따라서, 장기간의 고지방 식이로 염증성 장질환이 유도된 실험동물로부터 LTB4 농도를 측정하여 염증 정도를 분석하였다. 도 3에 나타난 바와 같이, 고지방 식이를 통해 염증성 장질환이 유도된 경우 1357 pg/㎖로, LTB4 농도가 정상 사료군(NC)에 비해 현저히 증가하였음을 알 수 있다. 이에 반해 가르시니아 캄보지아 추출물을 고지방 식이와 병행 투여한 양성 대조군(GC)에서는 LTB4 농도가 976 pg/㎖로 감소하였음을 확인하였다.leukotriene B4 (LTB 4 ) is known to be involved in the activity of inflammatory cells by inducing an inflammatory response in immune cells. Therefore, the level of inflammation was analyzed by measuring the LTB 4 concentration from experimental animals in which inflammatory bowel disease was induced by a long-term high fat diet. As shown in FIG. 3, when inflammatory bowel disease was induced through a high-fat diet, it can be seen that the concentration of LTB 4 was significantly increased to 1357 pg/ml compared to the normal feed group (NC). On the other hand, it was confirmed that the LTB 4 concentration decreased to 976 pg/ml in the positive control group (GC) in which garcinia cambogia extract was administered concurrently with a high fat diet.
실시예 1로부터 제조된 고춧잎 열수 추출물을 고지방 식이와 병행 투여한 제1, 제2실험군 역시 LTB4 농도가 각각 1177 pg/㎖, 1026 pg/㎖으로 감소하였음을 확인하였다. It was also confirmed that the concentration of LTB 4 decreased to 1177 pg/ml and 1026 pg/ml, respectively, in the first and second experimental groups, in which the hot water extract of red pepper leaf prepared in Example 1 was administered in parallel with a high fat diet.
또한 본 발명에 따른 고춧잎 열수 추출물은 양성 대조군 및 정상 사료군과 유사한 정도의 LTB4 농도 감소를 나타내었으며, 이를 통해 가르시니아 캄보지아 추출물과 동등한 정도의 LTB4 생성 억제 효과를 갖고 있음을 알 수 있다.In addition, the hot water extract of red pepper leaves according to the present invention showed a decrease in the concentration of LTB 4 similar to that of the positive control group and the normal feed group, through which it can be seen that it has an effect of inhibiting LTB 4 production equivalent to that of the garcinia cambogia extract.
비록 고춧잎 열수 추출물을 투여한 제1, 2실험군이 양성 대조군보다 LTB4 농도의 감소량이 적었으나, 가르시니아 캄보지아 추출물의 경우 각종 부작용이 야기될 수 있다는 문제점이 있는 반면, 본원발명의 고춧잎 열수 추출물은 매우 안정한 물질로, 세포 독성을 전혀 나타내지 않으면서도 현저한 염증억제 효과를 나타낸다는 점에서 현저히 우수한 효과를 가지고 있음을 알 수 있다.Although the 1st and 2nd experiment groups to which hot water extract of red pepper leaves were administered had less decrease in LTB 4 concentration than the positive control group, there is a problem that various side effects may occur in the case of the Garcinia cambogia extract, whereas the hot water extract of red pepper leaves of the present invention is very As a stable substance, it can be seen that it has a remarkably excellent effect in that it exhibits a remarkable anti-inflammatory effect without showing any cytotoxicity.
본 발명에 따른 고춧잎 열수 추출물은 염증세포의 활성을 억제시켜 염증성 장질환 개선, 예방 또는 치료에 효과를 나타낼 수 있음을 확인하였다. 나아가 LTB4 생성에 대해서, 정상 사료군 수준으로 억제시키는 현저한 활성까지 얻기 위해서는 상기 고춧잎 열수 추출물이 100 ㎎/㎖ 농도로 투여되는 것이 바람직하다.It was confirmed that the hot water extract of red pepper leaf according to the present invention can exhibit an effect in improving, preventing or treating inflammatory bowel disease by inhibiting the activity of inflammatory cells. Furthermore , in order to obtain a remarkable activity of inhibiting LTB 4 production at the level of a normal feed group, the hot water extract of pepper leaves is preferably administered at a concentration of 100 mg/ml.
시험예 3. 고춧잎 열수 추출물의 장누수증후군(leaky gut syndrome) 개선, 예방 또는 치료 효과Test Example 3. Effect of hot water extract of red pepper leaves on improving, preventing or treating leaky gut syndrome
1) 실험동물1) Experimental animals
우선, 6주령의 수컷 C57BL/6J mouse 45 마리를 중앙실험동물을 통해 구입하였다. 상기 실험동물은 다음과 같이 다섯 그룹으로 분리하였다. 각 그룹당 9마리의 실험동물을 사용하였고, 8주간의 식이를 진행한 후 장누수증후군에 대한 개선, 예방 및 치료 효능을 평가하였다.First, 45 6-week-old male C57BL/6J mice were purchased through a central laboratory animal. The experimental animals were divided into five groups as follows. Nine experimental animals were used for each group, and after 8 weeks of diet, the efficacy of improvement, prevention and treatment for intestinal leak syndrome were evaluated.
- 정상 사료군(NC): 정상 사료(AIN-93G)를 먹이고, vehicle만을 경구투여 한 실험군-Normal feed group (NC): An experimental group fed with normal feed (AIN-93G) and administered only the vehicle orally
- 고지방 식이군(HFD): 고지방(60% kcal fat) 사료를 먹이고, vehicle만을 경구투여 한 실험군-High fat diet group (HFD): Experimental group that fed high fat (60% kcal fat) feed and administered only vehicle orally
- 양성 대조군(GC): 고지방 사료를 먹이고, 가르시니아 캄보지아 추출물 50 ㎎/㎏을 경구투여 한 실험군-Positive control group (GC): An experimental group fed with a high-fat feed and orally administered 50 mg/kg of garcinia cambogia extract
- 제1실험군(WEPL50): 고지방 사료를 먹이고, 실시예 1로부터 제조된 고춧잎 열수 추출물 50 ㎎/㎏을 경구투여 한 실험군-Experimental group 1 (WEPL50): an experimental group in which 50 mg/kg of hot water extract of red pepper leaves prepared in Example 1 was orally administered after feeding a high-fat feed
- 제2실험군(WEPL100): 고지방 사료를 먹이고, 실시예 1로부터 제조된 고춧잎 열수 추출물 100 ㎎/㎏을 경구투여 한 실험군으로 구성하였다. -2nd experimental group (WEPL100): A high-fat feed was fed, and 100 mg/kg of hot water extract of red pepper leaves prepared in Example 1 was administered orally.
이때, 고지방 사료는 Lard를 첨가하여 열량을 60 cal%를 증가시킨 Modified AIN 76A purified rodent diet(60 cal% fat)를 사용하였다.At this time, a modified AIN 76A purified rodent diet (60 cal% fat) was used as a high fat diet, which increased calorie by 60 cal% by adding Lard.
2) 분석2) analysis
8주의 식이 기간이 끝나고, 분석하기 6시간 전부터 각 그룹의 실험동물을 절식시켰다. 각 실험동물들로부터 장 투과성을 확인하기 위해 멸균생리식염수에 녹인 FITC-dextran 400 mg/kg body weight을 경구투여한 후 0, 2, 4시간 뒤에 미정맥 채혈을 진행하였다. 얻어진 100 μL의 혈액을 원심분리(12,000 ×g, 10 min, 4 ℃)하여 상등액을 취하였고 이를 microplate reader기를 이용하여 여기파장(excitation wavelength)은 485 nm, 방출파장(emission wavelength)은 535 nm로 설정하여 흡광도를 측정하였다. 이는 FITC-dextran의 표준 곡선을 이용하여 농도를 산출하였고, 시간대 별 FITC-dextran 농도를 곡선아래면적(AUC, area under the curve)로 나타내었다.After the 8-week diet period was over, the experimental animals of each group were fasted from 6 hours before analysis. In order to confirm the intestinal permeability from each experimental animal, FITC-
3) 분석결과3) Analysis result
도 4는 정상 사료군(NC), 고지방 식이군(HFD), 양성 대조군(GC), 제1실험군(WEPL50) 및 제2실험군(WEPL100)에서의 FITC-dextran 검출농도를 시간에 따라 측정하여 나타낸 그래프이다. 도 5는 도 4로부터 측정된 결과의 곡선아래 면적을 계산하여 그래프로 나타낸 것이다.Figure 4 shows the detection concentration of FITC-dextran in the normal feed group (NC), the high fat diet group (HFD), the positive control group (GC), the first experimental group (WEPL50), and the second experimental group (WEPL100) over time. It is a graph. 5 is a graph showing the area under the curve of the result measured from FIG. 4.
도 4, 5에 나타난 바와 같이, 정상 사료군(NC)(normal control)을 100%로 하였을 때, 고지방 식이를 통해 장누수증후군이 야기된 고지방 식이군(HFD)은 399.61%였고, 양성 대조군(GC)는 271.71%로 검출되었다. 즉 고지방 식이가 제공되었어도 가르시니아 캄보지아 추출물이 병용 투여되면 장 투과성이 억제됨을 알 수 있다.As shown in Figs. 4 and 5, when the normal feed group (NC) (normal control) was set to 100%, the high fat diet group (HFD) caused by leaky gut syndrome through a high fat diet was 399.61%, and the positive control group (normal control) was 399.61%. GC) was detected as 271.71%. That is, it can be seen that even if a high-fat diet was provided, intestinal permeability was suppressed when garcinia cambogia extract was administered in combination.
그러나, 실시예 1로부터 제조된 고춧잎 열수 추출물이 병용 투여된 제1, 2실험군에서는 각각 125.97%, 104.98%로 측정된 바, 이는 정상 사료군과 상당히 유사한 수치까지 장투과성이 억제 및 감소됨을 알 수 있다. 특히 실시예 1로부터 제조된 고춧잎 열수 추추출물이 100 ㎎/㎏ 이상 투여된 것이 가장 효과가 우수함을 확인하였다.However, in the 1st and 2nd experimental groups to which the hot water extract prepared from Example 1 was co-administered, it was measured to be 125.97% and 104.98%, respectively, and it can be seen that the intestinal permeability was suppressed and decreased to a value that was quite similar to that of the normal feed group have. In particular, it was confirmed that the hot water extract of red pepper leaf prepared in Example 1 was administered at least 100 mg/kg to have the best effect.
제1, 제2실험군은 고지방 식이군(HFD)에 비해, 장투과성이 각각 3.17배, 3.81배 감소하였다. 따라서 본 발명에 따른 고춧잎 열수 추출물은 장누수증후군에 대해 개선, 예방 또는 치료 효과가 있음을 알 수 있다.Compared to the high fat diet group (HFD), intestinal permeability decreased by 3.17 times and 3.81 times in the first and second experimental groups, respectively. Therefore, it can be seen that the hot water extract of red pepper leaves according to the present invention has an improvement, prevention, or treatment effect on leaky intestinal syndrome.
하기에 본 발명의 분말을 함유하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, examples of the formulation of the composition containing the powder of the present invention will be described, but the present invention is not intended to limit this, but is intended to be described in detail.
제제예 1. 산제의 제조Formulation Example 1. Preparation of powder
실시예 1에서 얻은 고춧잎 열수 추출물 또는 실시예 2에서 얻은 고춧잎 고분자 분획물 500 ㎎Hot water extract of red pepper leaves obtained in Example 1 or 500 mg of polymer fraction of red pepper leaves obtained in Example 2
유당 100 ㎎100 mg lactose
탈크 10 ㎎
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예 2. 정제의 제조Formulation Example 2. Preparation of tablets
실시예 1에서 얻은 고춧잎 열수 추출물 또는 실시예 2에서 얻은 고춧잎 고분자 분획물 300 ㎎Hot water extract of red pepper leaves obtained in Example 1 or 300 mg of polymer fraction of red pepper leaves obtained in Example 2
옥수수전분 100 ㎎
유당 100 ㎎100 mg lactose
스테아린산 마그네슘 2 ㎎2 mg of magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above ingredients, tablets are prepared by tableting according to a conventional tablet manufacturing method.
제제예 3. 캅셀제의 제조Formulation Example 3. Preparation of Capsule
실시예 1에서 얻은 고춧잎 열수 추출물 또는 실시예 2에서 얻은 고춧잎 고분자 분획물 200 ㎎Red pepper leaf hot water extract obtained in Example 1 or 200 mg of red pepper leaf polymer fraction obtained in Example 2
결정성 셀룰로오스 3 ㎎
락토오스 14.8 ㎎Lactose 14.8 mg
마그네슘 스테아레이트 0.2 ㎎Magnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare a capsule.
제제예 4. 주사제의 제조Formulation Example 4. Preparation of injection
실시예 1에서 얻은 고춧잎 열수 추출물 또는 실시예 2에서 얻은 고춧잎 고분자 분획물 600 ㎎Hot water extract of red pepper leaves obtained in Example 1 or 600 mg of polymer fraction of red pepper leaves obtained in Example 2
만니톨 180 ㎎Mannitol 180 mg
주사용 멸균 증류수 2974 ㎎2974 mg of sterile distilled water for injection
Na2HPO4,12H2O 26 ㎎Na 2 HPO 4, 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플 당 상기의 성분 함량으로 제조한다.It is prepared in the amount of the above ingredients per ampoule according to a conventional injection preparation method.
제제예 5. 액제의 제조Formulation Example 5. Preparation of liquid formulation
실시예 1에서 얻은 고춧잎 열수 추출물 또는 실시예 2에서 얻은 고춧잎 고분자 분획물 4 gHot water extract of red pepper leaves obtained in Example 1 or 4 g of polymer fraction of red pepper leaves obtained in Example 2
이성화당 10 g10 g of isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water appropriate amount
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100g으로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.According to the usual preparation method of liquid formulations, add and dissolve each component in purified water, add an appropriate amount of lemon flavor, mix the above ingredients, add purified water and add purified water to adjust the total to 100 g, then fill in a brown bottle for sterilization. To prepare a liquid formulation.
제제예 6. 과립제의 제조Formulation Example 6. Preparation of granules
실시예 1에서 얻은 고춧잎 열수 추출물 또는 실시예 2에서 얻은 고춧잎 고분자 분획물 1,000 ㎎Hot water extract of red pepper leaves obtained in Example 1 or 1,000 mg of polymer fraction of red pepper leaves obtained in Example 2
비타민 혼합물 적량The right amount of vitamin mixture
비타민 A 아세테이트 70 ㎍Vitamin A acetate 70 ㎍
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎Vitamin B1 0.13 mg
비타민 B2 0.15 ㎎Vitamin B2 0.15 mg
비타민 B6 0.5 ㎎Vitamin B6 0.5 mg
비타민 B12 0.2 ㎍Vitamin B12 0.2 ㎍
비타민 C 10 ㎎
비오틴 10 ㎍Biotin 10 ㎍
니코틴산아미드 1.7 ㎎Nicotinic acid amide 1.7 mg
엽산 50 ㎍Folic acid 50 ㎍
판토텐산 칼슘 0.5 ㎎0.5 mg of calcium pantothenate
무기질 혼합물 적량Suitable amount of inorganic mixture
황산제1철 1.75 ㎎Ferrous sulfate 1.75 mg
산화아연 0.82 ㎎Zinc oxide 0.82 mg
탄산마그네슘 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎Potassium monophosphate 15 mg
제2인산칼슘 55 ㎎Dicalcium phosphate 55 mg
구연산칼륨 90 ㎎Potassium citrate 90 mg
탄산칼슘 100 ㎎100 mg of calcium carbonate
염화마그네슘 24.8 ㎎Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 과립제에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 과립제 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능식품 조성물 제조에 사용할 수 있다.The composition ratio of the vitamin and mineral mixture is relatively suitable for granules, but it is also possible to arbitrarily modify the mixing ratio. And can be used to prepare a health functional food composition according to a conventional method.
제제예 7. 기능성 음료의 제조Formulation Example 7. Preparation of functional beverage
실시예 1에서 얻은 고춧잎 열수 추출물 또는 실시예 2에서 얻은 고춧잎 고분자 분획물 1,000 ㎎Hot water extract of red pepper leaves obtained in Example 1 or 1,000 mg of polymer fraction of red pepper leaves obtained in Example 2
구연산 1,000 ㎎Citric acid 1,000 mg
올리고당 100 g100 g oligosaccharides
매실농축액 2 g2 g of plum concentrate
타우린 1 g1 g taurine
정제수를 가하여 전체 900 ㎖Total 900 ml by adding purified water
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 기능성 음료 조성물 제조에 사용한다. After mixing the above ingredients according to the normal health drink manufacturing method, stirring and heating the mixture at 85°C for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized, and then stored in a refrigerator. It is used to prepare the functional beverage composition of the present invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.The composition ratio is a mixture of ingredients suitable for a relatively preferred beverage in a preferred embodiment, but the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as the demand class, the country of demand, and the purpose of use.
Claims (12)
상기 조성물은 고지방 식이에서 IgA 발현을 증진시키고, IL-6의 발현과 LTB4 발현을 억제 또는 감소시키는 것을 특징으로 하는 장누수증후군 개선 또는 예방용 식품 조성물.The method of claim 1,
The composition is a food composition for improving or preventing leaky gut syndrome, characterized in that it enhances IgA expression in a high fat diet and inhibits or reduces the expression of IL-6 and LTB 4.
상기 장누수증후군은 고지방 식이에 의해 유도된 것을 특징으로 하는 장누수증후군 개선 또는 예방용 식품 조성물.The method of claim 1,
The leaky gut syndrome is a food composition for improving or preventing leaky gut syndrome, characterized in that induced by a high fat diet.
상기 조성물은 고지방 식에서 IgA 발현을 증진시키고, IL-6의 발현과 LTB4 발현을 억제 또는 감소시키는 것을 특징으로 하는 장누수증후군 예방 또는 치료용 약학 조성물.The method of claim 7,
The composition is a pharmaceutical composition for preventing or treating leaky gut syndrome, characterized in that it enhances IgA expression in a high-fat diet and inhibits or reduces the expression of IL-6 and LTB 4.
상기 장누수증후군은 고지방 식이에 의해 유도된 것을 특징으로 하는 장누수증후군 예방 또는 치료용 약학 조성물.The method of claim 7,
The leaky gut syndrome is a pharmaceutical composition for preventing or treating leaky gut syndrome, characterized in that induced by a high fat diet.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190049157A KR102233744B1 (en) | 2019-04-26 | 2019-04-26 | Composition for improvementing, preventing or treating leaky gut syndrome comprising fractions or extract of pepper leave |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190049157A KR102233744B1 (en) | 2019-04-26 | 2019-04-26 | Composition for improvementing, preventing or treating leaky gut syndrome comprising fractions or extract of pepper leave |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200125206A KR20200125206A (en) | 2020-11-04 |
KR102233744B1 true KR102233744B1 (en) | 2021-03-30 |
Family
ID=73571332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190049157A KR102233744B1 (en) | 2019-04-26 | 2019-04-26 | Composition for improvementing, preventing or treating leaky gut syndrome comprising fractions or extract of pepper leave |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102233744B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100487945B1 (en) * | 2001-08-31 | 2005-05-11 | 주식회사 경인제약 | An extract from leaf of Capsicum annuum for increasing immunity and the method of preparation thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101325849B1 (en) | 2010-12-16 | 2013-11-05 | 김유석 | Chungkookjang for preventing or improving diabetes comprising extracts of pepper leaves and method for preparation thereof |
-
2019
- 2019-04-26 KR KR1020190049157A patent/KR102233744B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100487945B1 (en) * | 2001-08-31 | 2005-05-11 | 주식회사 경인제약 | An extract from leaf of Capsicum annuum for increasing immunity and the method of preparation thereof |
Non-Patent Citations (3)
Title |
---|
우홍배 외 9인. 고추잎 추출물을 이용한 항비만 효과 검증. 한국식품영양과학회 학술대회발표집. 2016.10, p. 469 1부.* |
이종성 외 11인. NF-kappaB 프로모터 활성을 억제하는 식물추출물. Journal of the society of cosmetic scientists of Korea. Vol. 32, No. 3, 2006년 9월, pp. 135-140 1부.* |
장누수 증후군과 반건강. 월간암. 2016.10.11., [2020.06.27. 검색], 인터넷: <URL: http://www.cancerline.co.kr/html/15569.html> 1부.* |
Also Published As
Publication number | Publication date |
---|---|
KR20200125206A (en) | 2020-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102233749B1 (en) | Composition for improvementing, preventing or treating intestinal inflammation or leaky gut syndrome comprising fractions or extract of molokhia leave | |
KR101715274B1 (en) | Composition containing extract or fractions of Chrysanthemum indicum L. for treating, improving or preventing inflammatory disease | |
KR102411434B1 (en) | Composition for improvementing, preventing or treating obesity and metabolic diseases comprising fractions or extract of radish leave | |
US12076356B2 (en) | Composition comprising Molokhia extract as active ingredient for improving gut microbiome or for alleviating, preventing, or treating intestinal inflammation, leaky gut syndrome, obesity, or metabolic disease | |
KR101775062B1 (en) | Korean medicinal tea having strong anti-platelet aggregation activity and high acceptability | |
KR102416786B1 (en) | Composition for improvementing, preventing or treating obesity and metabolic diseases comprising fractions or extract of pepper leave | |
KR102315959B1 (en) | A composition for reinforcing immune function comprising the extract of oat sprout | |
KR102294288B1 (en) | Polysaccharide fraction isolated from Nelumbo nucifera leaf with immune-enhancing activity and method for producing the same | |
KR102233744B1 (en) | Composition for improvementing, preventing or treating leaky gut syndrome comprising fractions or extract of pepper leave | |
KR101692889B1 (en) | Composition comprising an extract or a fraction of Daphne kamtschatica for preventing or treating inflammatory diseases | |
KR102223635B1 (en) | Composition for improvementing, preventing or treating intestinal inflammation or leaky gut syndrome comprising fractions or extract of radish leave | |
KR20220067467A (en) | A composition comprising the ethanol extract of Corchorus olitorius for the prevention or treatment of alcoholic liver damage | |
KR102133473B1 (en) | A composition as a prebiotic for improving intestinal microflora containing sweet potato vines | |
KR102411428B1 (en) | Composition for improvementing, preventing or treating obesity and metabolic diseases comprising fractions or extract of molokhia leave | |
KR102042151B1 (en) | A composition as a prebiotic for improving intestinal microflora containing extract from pepper leaves | |
KR20220082396A (en) | Composition for preventing, ameliorating or treating allergic disease comprising Spatholobus suberectus extract as effective component | |
KR102114271B1 (en) | Pharmaceutical composition for anti-inflammatory Ethanol Extract of Antirrhinum majus as an active ingradient | |
KR100888068B1 (en) | Compositions for suppressing obesity | |
KR102183916B1 (en) | Composition containing complex extracts for preventing, improving or treating dyslipidemia | |
KR102183915B1 (en) | Composition containing complex extracts for improving blood circulation | |
KR101711397B1 (en) | Pharmaceutical compositions and health functional foods comprising Persicaria fauriei extracts for preventing or treating anticancer agent-induced of hematopoietic toxicity | |
KR101684574B1 (en) | Pharmaceutical compositions and health functional foods comprising Cibotium barometz J. Smith extracts for preventing or treating anticancer agent-induced of hematopoietic toxicity | |
KR102036860B1 (en) | A composition as a prebiotic for improving intestinal microflora containing corchorous olitorius | |
KR101620160B1 (en) | Composition for the prevention or treatment of Inflammatory Bowel Disease comprising extract of Atractylodes spp, and Poncirus trifoliata | |
KR102176394B1 (en) | A composition for immune enhancement comprising taheebo extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |